OncoCyte (NASDAQ:OCX) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement. Analysts estimate that OncoCyte will ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded ...

IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward ...

Oncocyte Corp., a diagnostics technology company, plans to use $29.1 million in new funds to drive development and commercialization efforts of its transplant assay. The company’s five largest ...

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after ...

OncoCyte Corp, which is developing diagnostics in the fledgling field of liquid biopsies, said on Monday a 300-patient validation study of its blood test for early detection of lung cancer has ...

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies ...

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ...

Management reiterated that they are on track to submit their FDA package by the end of 2025, consistent with prior communications. The target remains FDA approval in the first half of 2026. The goal ...